^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
OncoScreen™ IO

Type:
Laboratory Developed Test
Related tests:

Details

Evidence
OncoScreen™ IO is a pan-cancer test for tissue sample and detects important immune-oncology biomarkers including TMB and MSI, as well as rare but clinically actionable biomarkers, such as NTRK fusions, which provide important insights for therapy selection.
Cancer:
Bladder Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer, Solid Tumor
Gene:
MSI (Microsatellite instability), NTRK (Neurotrophic receptor tyrosine kinase), PD-L1 (Programmed death ligand 1), TMB (Tumor Mutational Burden)
Drug:
Cejemly (sugemalimab)
Method:
Next-Generation Sequencing (NGS)